ABUS - Arbutus Biopharma Corp
4.29
-0.160 -3.730%
Share volume: 1,383,401
Last Updated: 03-27-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.20%
PREVIOUS CLOSE
CHG
CHG%
$4.45
-0.16
-0.04%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-02-2024 | 08-08-2024 | 11-06-2024 | 03-27-2025 | 05-14-2025 | 08-06-2025 | 11-13-2025 | 03-23-2026 | |
| Total revenue | 1.532 M | 1.726 M | 1.339 M | 1.574 M | 1.764 M | 10.739 M | 529.000 K | 1.051 M | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 1.532 M | 1.726 M | 1.339 M | 1.574 M | 1.764 M | 10.739 M | 529.000 K | 1.051 M | |
| 12.66% | -22.42% | 17.55% | 12.07% | 508.79% | -95.07% | 98.68% | |||
| Operating expenses | 20.715 M | 23.098 M | 18.810 M | 13.522 M | 14.791 M | 8.826 M | 8.822 M | 8.695 M | |
| Selling general and admin | 5.312 M | 7.547 M | 4.537 M | 4.712 M | 5.832 M | 3.328 M | 3.044 M | 3.689 M | |
| Research and development | 15.403 M | 15.551 M | 14.273 M | 8.810 M | 8.959 M | 5.498 M | 5.778 M | 5.006 M | |
| Total expenses | 20.895 M | 23.309 M | 22.779 M | 15.507 M | 27.463 M | 9.251 M | 9.188 M | 6.341 M | |
| 11.55% | -2.27% | -31.92% | 77.10% | -66.31% | -0.68% | -30.99% | |||
| Operating income | -19.363 M | -21.583 M | -21.440 M | -13.933 M | -25.699 M | 1.488 M | -8.659 M | -5.290 M | |
| Ebit | -19.376 M | -21.591 M | -21.435 M | -13.966 M | -25.695 M | 1.509 M | -8.671 M | -4.615 M | |
| Pretax income | -17.875 M | -19.796 M | -19.717 M | -12.532 M | -24.526 M | 2.523 M | -7.742 M | -3.756 M | |
| 10.75% | -0.40% | -36.44% | 95.71% | -110.29% | -406.86% | -51.49% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -17.875 M | -19.796 M | -19.717 M | -12.532 M | -24.526 M | 2.523 M | -7.742 M | -3.756 M | |
| -10.75% | 0.40% | 36.44% | -95.71% | 110.29% | -406.86% | 51.49% |